Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN).

Full DD Report for BMRN

You must become a subscriber to view this report.


Recent News from (NASDAQ: BMRN)

BioMarin Announces 1 Platform and 3 Poster Presentations at World Federation of Hemophilia 2018 World Congress
SAN RAFAEL, Calif. , May 17, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the company will present data in one platform presentation and three poster presentations at the World Federation of Hemophilia (WFH) 2018 World Congress from May 20-24 ...
Source: PR Newswire
Date: May, 17 2018 16:05
BioMarin starts Phase 1/2 study of gene therapy for hemophilia A subgroup
Dosing is underway in a Phase 1/2 clinical trial, BMN 270-203 , assessing BioMarin Pharmaceutical's (NASDAQ: BMRN ) gene therapy valoctocogene roxaparvovec in patients with severe hemophilia A with pre-existing AAV5 antibodies. More news on: BioMarin Pharmaceutical Inc., Healthcare sto...
Source: SeekingAlpha
Date: May, 15 2018 09:29
BioMarin Announces First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy in Severe Hemophilia A Patients with Pre-existing AAV5 Antibodies
SAN RAFAEL, Calif. , May 15, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has dosed the first patient in a Phase 1/2 study (BMN 270-203) evaluating its investigational gene therapy, valoctocogene roxaparvovec, in severe hemophilia A patient...
Source: PR Newswire
Date: May, 15 2018 08:30
Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Omeros Corporation
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / U.S. markets eked out gains on Thursday, on the back of positive economic data and strong performance from the technology sector. The technology sector has gained almost 7% in May which is a much steeper gain than any other sector. The Dow Jones In...
Source: ACCESSWIRE IA
Date: May, 11 2018 08:00
New Research: Key Drivers of Growth for Harley-Davidson, BioMarin Pharmaceutical, Acadia Healthcare, Parker Drilling, NCR, and New York Community - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, May 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Harley-Davidson, Inc. (NYSE:HOG), BioMarin Pharmaceutical Inc. (NASDAQ:BMR...
Source: GlobeNewswire
Date: May, 11 2018 07:50
FANG Stocks Have Ignited A Rally - Cramer's Mad Money (5/10/18)
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , May 10. The market has been seeing negativity and selloff in the recent past. However, the non-believers have been converted to believers now. How did this happen? All it took was great earnings...
Source: SeekingAlpha
Date: May, 11 2018 07:38
FDA Ad Com Friday on trial design for achondroplasia
The FDA's Pediatric Advisory Committee will meet on Friday, May 11, to discuss the necessary design and objectives for clinical trials of drugs to treat achondroplasia , a rare inherited bone growth disorder characterized by dwarfism. More news on: Ascendis Pharma, BioMarin Pharmaceutic...
Source: SeekingAlpha
Date: May, 09 2018 15:44
Our Free Research Report on Biogen and More Biotech Stocks
Stock Research Monitor: AVXS, BHVN, and BMRN LONDON, UK / ACCESSWIRE / May 9, 2018 / If you want a free Stock Review on BIIB sign up now at www.wallstequities.com/registration . On Tuesday, May 08, 2018, US markets saw four out of nine sectors finishing the day in green, four in re...
Source: ACCESSWIRE IA
Date: May, 09 2018 07:35
Bright Lights On Capitalist Woodstock, Tech Developers And Sports Betting
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Macro matters: Traders are back to focusing on economic reports after no major deve...
Source: SeekingAlpha
Date: May, 05 2018 08:33
BioMarin Named To Forbes List Of America's Best Mid-size Employers
SAN RAFAEL, Calif. , May 1, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has been ranked 51st overall among 500 companies on Forbes magazine's 2018 list of "America's Best Mid-size Employers," and third among companies in the biotechnology ...
Source: PR Newswire
Date: May, 01 2018 12:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1799.99101.01101.59599.3211,411,338
2018-08-16102.31100.32102.5099.9851,297,326
2018-08-15102.28101.81103.15101.33720,620
2018-08-14103.22103.14103.81102.44634,682
2018-08-13101.42102.72103.08101.42919,445

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17117,628459,85925.5791Cover
2018-08-1669,300349,46219.8305Cover
2018-08-1572,478156,58046.2882Short
2018-08-1474,743150,97349.5075Short
2018-08-1392,848248,07937.4268Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BMRN.


About BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN)

Logo for BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $15,822,910,136 - 05/14/2018
  • Issue and Outstanding: 176,713,314 - 04/13/2018

 


Recent Filings from (NASDAQ: BMRN)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 27 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 26 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 26 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 26 2018

 

 


Daily Technical Chart for (NASDAQ: BMRN)

Daily Technical Chart for (NASDAQ: BMRN)


Stay tuned for daily updates and more on (NASDAQ: BMRN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BMRN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BMRN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BMRN and does not buy, sell, or trade any shares of BMRN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/